AAA
TSHA icon

Affinity Asset Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Affinity Asset Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Buy
1,750,000
+750,000
+75% +$4.44M 0.54% 56
2026
Q1 		$4.47M Sell
1,000,000
-2,300,000
-70% -$10.7M 0.23% 74
2025
Q4 		$18.1M Buy
3,300,000
+300,000
+10% +$1.46M 1.03% 32
2025
Q3 		$9.81M Buy
3,000,000
+2,800,000
+1,400% +$7.93M 0.85% 34
2025
Q2 		$462K Buy
+200,000
New +$435K 0.06% 79

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Affinity Asset Advisors's TSHA Position: Q2 2026 in Review

Affinity Asset Advisors increased its Taysha Gene Therapies (TSHA) stake by 75% in Q2 2026, buying an estimated $4.44M and bringing the position to 1,750,000 shares worth $11.9M. The position accounts for 0.54% of the portfolio, ranked #56.

Affinity Asset Advisors first reported a position in TSHA in Q2 2025 and has held it in 5 quarters since. The position peaked at $18.1M in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Affinity Asset Advisors held 1,750,000 shares of Taysha Gene Therapies worth $11.9M as of Q2 2026.
  • Affinity Asset Advisors bought 750,000 Taysha Gene Therapies shares in Q2 2026, an estimated $4.44M.
  • Taysha Gene Therapies made up 0.54% of Affinity Asset Advisors's portfolio in Q2 2026, its #56 holding.
  • Affinity Asset Advisors first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 5 quarters since.
  • Affinity Asset Advisors's Taysha Gene Therapies position peaked at $18.1M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.